{
    "clinical_study": {
        "@rank": "63977", 
        "brief_summary": {
            "textblock": "To assess the safety and efficacy of itraconazole versus placebo for prevention of\n      histoplasmosis in HIV-infected patients with CD4 counts < 150 cells/mm3 who reside where\n      histoplasmosis is endemic. To assess the safety and efficacy of itraconazole for preventing\n      other debilitating fungal infections, such as cryptococcosis, aspergillosis, recalcitrant\n      oropharyngeal or vaginal candidiasis, and recurrent esophageal candidiasis."
        }, 
        "brief_title": "A Study of Itraconazole in the Prevention of Histoplasmosis, a Fungal Infection, in HIV-Infected Patients", 
        "condition": [
            "HIV Infections", 
            "Histoplasmosis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Acquired Immunodeficiency Syndrome", 
                "HIV Infections", 
                "Histoplasmosis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients must have:\n\n          -  HIV infection.\n\n          -  Residence in an area endemic for H. capsulatum.\n\n          -  Absolute CD4 count < 150 cells/mm3.\n\n          -  No current or past active histoplasmosis.\n\n          -  No other active fungal infection.\n\n          -  Life expectancy of at least 1 year.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following symptoms or conditions are excluded:\n\n          -  Life-threatening infection or malignancy other than cutaneous Kaposi's sarcoma.\n\n          -  Inability to take oral medication.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Systemically-active antifungals.\n\n          -  Investigational drugs (expanded access drugs are acceptable).\n\n          -  Rifampin.\n\n          -  Rifabutin.\n\n          -  Terfenadine.\n\n          -  Astemizole.\n\n          -  Phenobarbital.\n\n          -  Phenytoin.\n\n          -  Carbamazepine.\n\n          -  H2 blockers.\n\n          -  Omeprazole.\n\n          -  Continual antacids.\n\n        Patients with the following prior conditions are excluded:\n\n        History of intolerance to imidazole or azole compounds.\n\n        Prior Medication:\n\n        Excluded within 1 month prior to study entry:\n\n          -  Investigational drugs (expanded access drugs are acceptable).\n\n        Excluded within 15 days prior to study entry:\n\n          -  Rifampin.\n\n          -  Rifabutin.\n\n          -  Terfenadine.\n\n          -  Astemizole.\n\n          -  Phenobarbital.\n\n          -  Phenytoin.\n\n          -  Carbamazepine."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "13 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002438", 
            "org_study_id": "235B", 
            "secondary_id": [
                "MSG 28", 
                "ITR-USA-73"
            ]
        }, 
        "intervention": {
            "intervention_name": "Itraconazole", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Itraconazole", 
                "Hydroxyitraconazole"
            ]
        }, 
        "keyword": [
            "Itraconazole", 
            "Histoplasmosis", 
            "Acquired Immunodeficiency Syndrome"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46280"
                    }, 
                    "name": "Infectious Diseases of Indianapolis"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46202"
                    }, 
                    "name": "Infectious Diseases Research Clinic / Indiana Univ Hosp"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kansas City", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "64108"
                    }, 
                    "name": "Univ of Missouri at Kansas City School of Medicine"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kansas City", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "64132"
                    }, 
                    "name": "Infectious Diseases Association / Research Med Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Memphis", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "38103"
                    }, 
                    "name": "ASCC"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Memphis", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "38105"
                    }, 
                    "name": "Dr Michael Threikeld"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37232"
                    }, 
                    "name": "Dr Mark A Pierce"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Randomized Study Comparing Itraconazole to Placebo in the Prevention of Histoplasmosis in Patients With Human Immunodeficiency Virus Infection", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002438"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Janssen, LP", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 1996"
    }, 
    "geocoordinates": {
        "ASCC": "35.15 -90.049", 
        "Dr Mark A Pierce": "36.166 -86.784", 
        "Dr Michael Threikeld": "35.15 -90.049", 
        "Infectious Diseases Association / Research Med Ctr": "39.1 -94.579", 
        "Infectious Diseases Research Clinic / Indiana Univ Hosp": "39.769 -86.158", 
        "Infectious Diseases of Indianapolis": "39.769 -86.158", 
        "Univ of Missouri at Kansas City School of Medicine": "39.1 -94.579"
    }
}